文章：

基于循环肿瘤浆细胞（CTPC）在诊断时对MGUS和多发性骨髓瘤进行微创血液表征的下一代流式技术

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

原文发布日期：2018-11-19

DOI: 10.1038/s41408-018-0153-9

类型: Article

开放获取: 是

英文摘要：

Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p <0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p <0.0001) and a shorter survival in MM patients with active disease requiring treatment (p ≤ 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.

摘要翻译： 

在此，我们首次使用新一代流式细胞术（NGF）研究了新诊断的局部和系统性浆细胞肿瘤（PCN）患者外周血（PB）中循环肿瘤浆细胞（CTPC）的频率和数量，并将我们的发现与疾病的不同诊断和预后类别相关联。总体而言，研究了来自264名新诊断PCN患者的508个样本。CTPC在所有活动性多发性骨髓瘤（MM；100%）和冒烟型多发性骨髓瘤（SMM）患者（100%）的外周血中均被检测到，并且在超过一半（59%）的未定意义的单克隆丙种球蛋白病（MGUS）病例中也被检测到（p <0.0001）；相比之下，CTPC仅存在于一小部分孤立性浆细胞瘤患者（18%）中。外周血中较高的CTPC数量与较高的骨髓浸润水平和更不利的预后特征相关，同时与从MGUS进展到MM的时间更短（p <0.0001）以及需要治疗的活动性疾病MM患者的生存期更短（p ≤ 0.03）相关。总之，通过NGF在诊断时评估的外周血中CTPC的存在，成为播散性PCN的一个标志，较高的外周血CTPC数量与恶性疾病行为以及MGUS和MM的较差结局密切相关。

原文链接：

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)